📷 Image: Wikimedia Commons / Post of Hungary
Health
Study warns ending US newborn hepatitis B vaccine could boost infection risk
✍️ Mezha.net
🗓 21 Oct 2026, 05:34 AM
👁 16
A recent study cautions that discontinuing the routine hepatitis B shot for newborns in the United States may lead to a rise in hepatitis B infections.
A new research report has warned that halting the universal hepatitis B vaccination for newborns in the United States could increase the number of hepatitis B cases. The study examined epidemiological data and modelled scenarios where the birth‑dose vaccine is withdrawn, finding a measurable uptick in projected infections.
Currently, the Centers for Disease Control and Prevention recommends a single hepatitis B dose within 24 hours of birth, followed by two booster shots. This schedule has been credited with keeping the disease at historically low levels among American infants.
Public health experts say that removing the birth‑dose would leave newborns vulnerable during the critical first weeks of life, when mother‑to‑child transmission is most likely. The study urges policymakers to retain the newborn shot as a cornerstone of the country's hepatitis B prevention strategy.
The authors call for further monitoring and suggest that any consideration of policy change be backed by robust data and stakeholder consultation, emphasizing that premature removal could reverse decades of progress in disease control.
Currently, the Centers for Disease Control and Prevention recommends a single hepatitis B dose within 24 hours of birth, followed by two booster shots. This schedule has been credited with keeping the disease at historically low levels among American infants.
Public health experts say that removing the birth‑dose would leave newborns vulnerable during the critical first weeks of life, when mother‑to‑child transmission is most likely. The study urges policymakers to retain the newborn shot as a cornerstone of the country's hepatitis B prevention strategy.
The authors call for further monitoring and suggest that any consideration of policy change be backed by robust data and stakeholder consultation, emphasizing that premature removal could reverse decades of progress in disease control.